A review of first-line treatment for small-cell lung cancer (Q34003347)

30 July 2017

1 reference

title

A review of first-line treatment for small-cell lung cancer (English)

1 reference

30 July 2017

A Review of First-Line Treatment for Small-cell Lung Cancer (English)

0 references

1 reference

Nevin Murray

1

1 reference

30 July 2017

Andrew T Turrisi

series ordinal

2

1 reference

30 July 2017

Andrew T. Turrisi

series ordinal

2

0 references

publication date

1 March 2006

1 reference

Journal of Thoracic Oncology

30 July 2017

March 2006

0 references

published in

1 reference

30 July 2017

volume

1

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

270-278

1 reference

Current concepts in cancer: small-cell lung cancer

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Alkylating agents in bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Oat cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Multidisciplinary management of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicent

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Influence of age on the treatment of limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Applying radiobiological principles to combined modality treatment of head and neck cancer--the time factor

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Radiation sensitivity of human lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Thoracic radiotherapy for limited-stage small cell lung cancer: issues of timing, volumes, dose, and fractionation

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Radiation Dose Intensification in Limited-Stage Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

Brain irradiation and systemic chemotherapy for small-cell lung cancer: dangerous liaisons?

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931579-3

7 January 2021

10.1016/S1556-0864(15)31579-3

Identifiers

DOI

0 references

Fatcat ID

release_xceuvgpwcfatbnmybpz2lyqoce

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xceuvgpwcfatbnmybpz2lyqoce

24 November 2022

mapped directly with Wikidata item

1 reference